Bioxytran (BIXT) EPS (Diluted) Growth (1y) (2022 - 2026)
Bioxytran (BIXT) EPS (Diluted) Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 96.09% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 144.25% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 315.14% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -11.18% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -1,458.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.93% |
| Dec 31, 2025 | -4.76% |
| Sep 30, 2025 | -2.34% |
| Jun 30, 2025 | 110.65% |
| Mar 31, 2025 | -332.29% |
| Dec 31, 2024 | 37.70% |
| Sep 30, 2024 | 62.44% |
| Jun 30, 2024 | 66.67% |
| Mar 31, 2024 | 46.79% |
| Dec 31, 2023 | -15.82% |
| Sep 30, 2023 | -373.52% |
| Jun 30, 2023 | -96.52% |
| Mar 31, 2023 | 19.52% |
| Dec 31, 2022 | 13.17% |
| Sep 30, 2022 | 55.97% |
| Jun 30, 2022 | 23.53% |
| Mar 31, 2022 | 49.19% |